5.58
+0.37(+7.10%)
Currency In USD
| Previous Close | 5.21 |
| Open | 5.18 |
| Day High | 5.62 |
| Day Low | 5.15 |
| 52-Week High | 5.86 |
| 52-Week Low | 1.33 |
| Volume | 3.25M |
| Average Volume | 2.01M |
| Market Cap | 771.64M |
| PE | -12.4 |
| EPS | -0.45 |
| Moving Average 50 Days | 4.95 |
| Moving Average 200 Days | 3.34 |
| Change | 0.37 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $656.47 as of January 14, 2026 at a share price of $5.58. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $1,116 as of January 14, 2026 at a share price of $5.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics Provides Corporate Update
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (B
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jan 05, 2026 9:30 PM GMT
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced i
Compass Therapeutics Announces Key Leadership Appointments
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced t